Profitability
by Company within Major Pharmaceutical Preparations Industry
|
Company |
Quarter |
Gross Margin |
Net Margin |
Cash flow Margin |
ROE |
Aadi Bioscience Inc |
2 Q |
89.42% |
-289.76% |
- |
-40.72% |
Abbvie Inc |
2 Q |
69.42% |
14.62% |
14.77% |
58.42% |
Abcellera Biologics Inc |
2 Q |
- |
-303.58% |
-131.97% |
-6.05% |
Abeona Therapeutics Inc |
2 Q |
- |
-425.17% |
39.44% |
-207.07% |
American Bio Medica Corporation |
1 Q |
45.12% |
- |
20.73% |
- |
Abbott Laboratories |
2 Q |
55.07% |
13.78% |
-13.29% |
14% |
Arbutus Biopharma Corp |
2 Q |
- |
-367.53% |
-287.62% |
-5.65% |
Abvc Biopharma Inc |
2 Q |
-1094.65% |
-37898.59% |
-17182.66% |
-485.19% |
Acadia Pharmaceuticals Inc |
2 Q |
95.49% |
0.67% |
-109.3% |
-27.77% |
Acer Therapeutics Inc |
2 Q |
- |
- |
- |
- |
Adicet Bio Inc |
2 Q |
- |
- |
- |
-41.3% |
Ac Immune Sa |
4 Q |
- |
- |
- |
-31.47% |
Aclaris Therapeutics Inc |
2 Q |
44.25% |
-1582.08% |
-726.16% |
-54.43% |
Acrivon Therapeutics Inc |
2 Q |
- |
- |
- |
-24.55% |
Acelrx Pharmaceuticals Inc |
2 Q |
- |
-1727.67% |
-2349.01% |
-173.66% |
Acasti Pharma Inc |
2 Q |
- |
- |
- |
-51% |
Acura Pharmaceuticals inc |
4 Q |
- |
80.56% |
-66.67% |
- |
Accustem Sciences Inc |
2 Q |
- |
- |
- |
- |
Acurx Pharmaceuticals inc |
2 Q |
- |
- |
- |
-183.88% |
Adc Therapeutics Sa |
4 Q |
95.89% |
-678.2% |
- |
-138.5% |
Adial Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-231.92% |
Adamis Pharmaceuticals Corporation |
2 Q |
-5103.66% |
-123457.48% |
-34981.9% |
- |
Adamas Pharmaceuticals Inc |
3 Q |
97.78% |
-75.37% |
-39.29% |
- |
Aditxt Inc |
2 Q |
15.95% |
-2571.3% |
-93.47% |
-775.4% |
Addex Therapeutics Ltd |
4 Q |
- |
-1462.57% |
- |
-312.48% |
Ayala Pharmaceuticals Inc |
2 Q |
0% |
-96655.56% |
-108511.11% |
-176.71% |
Aeterna Zentaris Inc |
4 Q |
97.22% |
-402.96% |
- |
-15.79% |
Kaya Holdings Inc |
2 Q |
64.23% |
-1295.73% |
- |
- |
Affimed N v |
4 Q |
- |
-207.98% |
- |
-37.62% |
Agex Therapeutics Inc |
2 Q |
44.44% |
-29766.67% |
- |
- |
Agios Pharmaceuticals Inc |
2 Q |
83.49% |
-1248.6% |
-288.83% |
-20.24% |
Aeglea Biotherapeutics Inc |
2 Q |
- |
-31552.47% |
- |
- |
Agile Therapeutics Inc |
2 Q |
61.51% |
-73.31% |
-31.64% |
- |
Ainos Inc |
2 Q |
-95.47% |
-8228.78% |
- |
-44.32% |
Akebia Therapeutics Inc |
4 Q |
- |
-16.74% |
-99.31% |
-350.61% |
Akero Therapeutics Inc |
2 Q |
- |
- |
- |
-29.01% |
Akari Therapeutics Plc |
4 Q |
- |
- |
- |
-991.1% |
Akouos inc |
3 Q |
- |
- |
- |
-45.09% |
Albireo Pharma inc |
3 Q |
93.78% |
-384.46% |
- |
-97.59% |
Aldeyra Therapeutics Inc |
2 Q |
- |
- |
- |
-35.88% |
Alimera Sciences Inc |
2 Q |
88.31% |
-58.6% |
33.25% |
- |
Alkermes Plc |
2 Q |
89.75% |
38.4% |
55.78% |
9.42% |
Allakos Inc |
2 Q |
- |
- |
- |
-50.87% |
Allarity Therapeutics Inc |
2 Q |
- |
- |
- |
- |
Alnylam Pharmaceuticals Inc |
2 Q |
76.37% |
-86.59% |
-4.53% |
- |
Alpine Immune Sciences Inc |
2 Q |
- |
-153.1% |
- |
-33.45% |
Aileron Therapeutics Inc |
2 Q |
- |
- |
- |
-102.25% |
Altimmune inc |
2 Q |
- |
-267683.33% |
-38850% |
-44.81% |
Alexion Pharmaceuticals Inc |
1 Q |
92.34% |
29.89% |
28.84% |
4.69% |
Alx Oncology Holdings Inc |
2 Q |
- |
- |
- |
-51.97% |
Alzamend Neuro Inc |
2 Q |
- |
- |
- |
-349.7% |
Amylyx Pharmaceuticals Inc |
2 Q |
94.32% |
22.47% |
- |
-23.8% |
Ampio Pharmaceuticals inc |
2 Q |
- |
- |
- |
-139.53% |
Amphastar Pharmaceuticals Inc |
2 Q |
49.92% |
17.93% |
-17.55% |
18.78% |
Amarin Corp Plcuk |
2 Q |
53.22% |
-21.9% |
51.87% |
-6.56% |
Amneal Pharmaceuticals Inc |
2 Q |
36.23% |
-43.37% |
-21.38% |
-82.1% |
Applied Molecular Transport Inc |
2 Q |
- |
- |
- |
-189.89% |
Amryt Pharma Plc |
4 Q |
52.32% |
0% |
53.38% |
0% |
Anaptysbio inc |
2 Q |
- |
-1151.59% |
-1715.49% |
-65.52% |
Anebulo Pharmaceuticals Inc |
1 Q |
- |
- |
- |
-73.81% |
Angion Biomedica Corp |
2 Q |
- |
-1399.54% |
-1474.73% |
-35.45% |
Ani Pharmaceuticals Inc |
2 Q |
63.72% |
5.36% |
80.61% |
-1.53% |
Anixa Biosciences Inc |
2 Q |
- |
- |
- |
-40.67% |
Annexon Inc |
2 Q |
- |
- |
- |
-64.31% |
An2 Therapeutics Inc |
2 Q |
- |
- |
- |
-58.52% |
Annovis Bio inc |
2 Q |
- |
- |
- |
-120.97% |
Apexigen Inc |
2 Q |
- |
- |
- |
-910.95% |
Apellis Pharmaceuticals Inc |
2 Q |
- |
-128.5% |
-156.91% |
-212.85% |
Applied Therapeutics Inc |
2 Q |
- |
- |
- |
-5544.59% |
Aptorum Group Limited |
4 Q |
- |
- |
- |
-154.88% |
Aprea Therapeutics Inc |
2 Q |
- |
- |
- |
-55.23% |
Aptinyx Inc |
1 Q |
- |
- |
- |
-157.89% |
Aptevo Therapeutics Inc |
2 Q |
- |
- |
- |
-95.36% |
Aquestive Therapeutics Inc |
2 Q |
50.03% |
-43.74% |
-33.58% |
- |
Aravive Inc |
2 Q |
- |
- |
0% |
- |
Arcturus Therapeutics Holdings Inc |
2 Q |
- |
-499.57% |
- |
31.17% |
Aridis Pharmaceuticals Inc |
1 Q |
- |
-629.94% |
-345.56% |
- |
Ardelyx inc |
1 Q |
86.48% |
-235.49% |
-32.13% |
-76.72% |
Arena Pharmaceuticals Inc |
4 Q |
- |
-288164.81% |
-300150% |
-69.83% |
Arcutis Biotherapeutics Inc |
2 Q |
85.05% |
-1367.84% |
- |
-188.88% |
Artelo Biosciences Inc |
2 Q |
- |
- |
- |
-50.18% |
Arvinas Inc |
2 Q |
- |
-122.2% |
-72.66% |
-78.32% |
Arrowhead Pharmaceuticals Inc |
2 Q |
- |
-657.98% |
-186.7% |
-44.34% |
Aslan Pharmaceuticals Limited |
4 Q |
- |
- |
- |
-377.64% |
Assembly Biosciences Inc |
2 Q |
- |
- |
- |
-104.9% |
Ascendis Pharma A |
4 Q |
76.28% |
-1139.63% |
- |
-221.45% |
Assertio Holdings inc |
2 Q |
88.36% |
20.66% |
3.83% |
45.16% |
Atai Life Sciences N v |
2 Q |
- |
-19634.3% |
-26043.6% |
-59.12% |
Alterity Therapeutics Limited |
2 Q |
- |
- |
- |
0% |
Athersys Inc |
2 Q |
- |
-26375.51% |
- |
- |
180 Life Sciences Corp |
2 Q |
- |
- |
- |
-403.09% |
Actinium Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-74.73% |
Athenex Inc |
4 Q |
75.22% |
-425.38% |
-143.85% |
- |
Atossa Therapeutics Inc |
2 Q |
- |
- |
- |
-27.49% |
Adhera Therapeutics Inc |
2 Q |
- |
- |
- |
- |
Avenue Therapeutics Inc |
2 Q |
- |
- |
- |
- |
Astria Therapeutics inc |
2 Q |
- |
- |
- |
-26.29% |
Aurinia Pharmaceuticals Inc |
2 Q |
96.23% |
-27.7% |
-17.58% |
-18.05% |
Avadel Pharmaceuticals Plc |
2 Q |
97.59% |
-4306.95% |
-2233.02% |
-799.61% |
Aveo Pharmaceuticals Inc |
3 Q |
86.98% |
-10.73% |
23.74% |
-81.66% |
Atea Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-16.82% |
Aerovate Therapeutics inc |
1 Q |
- |
- |
- |
-48.7% |
Avalo Therapeutics Inc |
2 Q |
-10.11% |
-1274.18% |
-1621.77% |
- |
Axim Biotechnologies Inc |
2 Q |
- |
-37499.19% |
- |
- |
Axsome Therapeutics Inc |
2 Q |
90.15% |
-143.83% |
- |
-112.21% |
Aytu Biopharma inc |
1 Q |
56.06% |
-31.67% |
-1.42% |
-71.3% |
Astrazeneca Plc |
4 Q |
72.06% |
7.42% |
13.9% |
8.89% |
Azitra Inc |
2 Q |
- |
-2575.31% |
- |
- |
Bridgebio Pharma Inc |
2 Q |
63.5% |
-9792.99% |
-6731.57% |
- |
Atreca inc |
2 Q |
- |
- |
- |
-120.73% |
Briacell Therapeutics Corp |
1 Q |
- |
- |
- |
0% |
Bicycle Therapeutics Plc |
2 Q |
- |
-373.81% |
- |
-54.71% |
Bioadaptives Inc |
2 Q |
63.7% |
-6152.93% |
- |
- |
Biodexa Pharmaceuticals Plc |
4 Q |
- |
-1095.28% |
0% |
-242.13% |
Biodelivery Sciences International Inc |
4 Q |
84% |
- |
31.51% |
63.64% |
Betterlife Pharma Inc. |
4 Q |
- |
- |
- |
-14.06% |
Bullfrog Ai Holdings Inc |
2 Q |
- |
- |
- |
- |
Biofrontera Inc |
2 Q |
- |
-168.21% |
-154.79% |
-128.79% |
Beigene Ltd |
2 Q |
83.87% |
-64.03% |
-20.53% |
-40.66% |
Bausch Health Companies Inc |
2 Q |
70.47% |
1.25% |
2.63% |
-68.17% |
Biohaven Ltd |
2 Q |
- |
- |
- |
-195.16% |
Biora Therapeutics Inc |
2 Q |
- |
-890350% |
-200550% |
- |
Biovie Inc |
3 Q |
- |
- |
- |
491.96% |
Bioxytran Inc |
2 Q |
- |
- |
- |
- |
Bellicum Pharmaceuticals Inc |
2 Q |
- |
-245066.67% |
- |
- |
Bellerophon Therapeutics inc |
2 Q |
- |
- |
- |
-189.42% |
Biolinerx Ltd |
4 Q |
- |
- |
- |
-53.21% |
Biomea Fusion Inc |
2 Q |
- |
- |
- |
-74.75% |
Biomarin Pharmaceutical Inc |
2 Q |
78.48% |
9.41% |
19.2% |
2.15% |
Bristol myers Squibb Company |
2 Q |
74.38% |
18.5% |
-5.55% |
24.97% |
Benitec Biopharma Inc |
2 Q |
- |
-66585.71% |
-22657.14% |
-274.34% |
Bolt Biotherapeutics Inc |
2 Q |
- |
-1260.08% |
-96.65% |
-46.56% |
Blueprint Medicines Corporation |
2 Q |
95.96% |
-230.66% |
-161.74% |
-117.88% |
Bio path Holdings Inc |
2 Q |
- |
- |
- |
-152.81% |
Biophytis Sa |
4 Q |
- |
- |
- |
-547.71% |
Bespoke Extracts Inc |
2 Q |
37.74% |
-246.97% |
-1.28% |
- |
Bioxcel Therapeutics Inc |
2 Q |
94.31% |
-11710.07% |
-8309.85% |
-309.07% |
Blue Water Biotech Inc |
1 Q |
- |
- |
- |
-64.24% |
Beyondspring Inc |
4 Q |
- |
-2685.42% |
-5026.79% |
- |
Calithera Biosciences Inc |
4 Q |
- |
- |
- |
-107.94% |
Calcimedica Inc |
2 Q |
- |
- |
- |
-147.85% |
Calliditas Therapeutics Ab |
4 Q |
98.11% |
-51.35% |
- |
-4.4% |
Can fite Biopharma Ltd |
4 Q |
- |
-1255.93% |
-478.77% |
-224.17% |
Capricor Therapeutics inc |
2 Q |
- |
-188.04% |
-19.61% |
-323.4% |
Cara Therapeutics inc |
2 Q |
79.55% |
-454.05% |
- |
-75.82% |
Carisma Therapeutics Inc |
2 Q |
- |
-2.47% |
- |
-19.43% |
Casi Pharmaceuticals inc |
4 Q |
63.28% |
-93.39% |
46.03% |
-90.31% |
Cymabay Therapeutics Inc |
2 Q |
- |
-2.61% |
-76.31% |
-104.52% |
Catalyst Biosciences Inc |
2 Q |
- |
- |
- |
- |
Chemocentryx Inc. |
2 Q |
96.59% |
-134.54% |
16.23% |
-48.52% |
Avid Bioservices Inc |
2 Q |
11.05% |
-5.64% |
-36.78% |
-1.66% |
Cardax Inc |
1 Q |
63.3% |
-1321.67% |
37.74% |
- |
Celularity Inc |
2 Q |
92.95% |
-1632.03% |
-185.43% |
-51.93% |
Chembio Diagnostics Inc |
4 Q |
45.78% |
-8.27% |
-27.8% |
-113.57% |
Cen Biotech Inc |
3 Q |
- |
-264.15% |
-94.3% |
- |
Cerevel Therapeutics Holdings Inc |
2 Q |
- |
- |
- |
-83.19% |
Contrafect Corporation |
2 Q |
- |
- |
- |
- |
China Health Industries Holdings Inc |
1 Q |
10.89% |
-1355.47% |
- |
-0.36% |
Chiasma Inc |
1 Q |
96.52% |
-1587.73% |
- |
-113.57% |
Cincor Pharma Inc |
3 Q |
- |
- |
- |
0% |
Cingulate Inc |
2 Q |
- |
- |
- |
-1235.85% |
Checkpoint Therapeutics inc |
2 Q |
- |
-53293.55% |
0% |
- |
Cell Source Inc |
1 Q |
- |
- |
- |
- |
Clene Inc |
2 Q |
75.46% |
-9346.84% |
-40.89% |
-1416.17% |
Cellectar Biosciences Inc |
2 Q |
- |
- |
- |
-419.32% |
Clearside Biomedical Inc |
2 Q |
79.08% |
-894.5% |
-630.06% |
-533.87% |
Clever Leaves Holdings Inc |
2 Q |
57.68% |
-76.07% |
-32.75% |
-125.46% |
Clovis Oncology inc |
3 Q |
76.31% |
-182.68% |
-118.25% |
- |
Chemomab Therapeutics Ltd |
1 Q |
- |
- |
- |
77.93% |
Clearmind Medicine Inc |
3 Q |
- |
- |
- |
- |
Compass Pathways Plc |
2 Q |
- |
- |
- |
-57.87% |
Comera Life Sciences Holdings Inc |
2 Q |
82.21% |
-448.06% |
-337.2% |
- |
Chimerix inc |
2 Q |
- |
-71446.15% |
- |
72.53% |
Cnbx Pharmaceuticals Inc |
2 Q |
- |
-49.87% |
-1.16% |
- |
Concert Pharmaceuticals Inc |
3 Q |
- |
-361300% |
-550700% |
-165.03% |
Cns Pharmaceuticals Inc |
2 Q |
- |
-51541.07% |
-10654.7% |
-318.2% |
Constellation Pharmaceuticals Inc |
1 Q |
- |
- |
- |
-33.12% |
Centessa Pharmaceuticals Plc |
2 Q |
- |
- |
- |
-54% |
Connect Biopharma Holdings Limited |
4 Q |
- |
- |
- |
-72.67% |
Context Therapeutics Inc |
2 Q |
- |
- |
- |
-59.67% |
Cocrystal Pharma Inc |
2 Q |
- |
- |
- |
-51.18% |
Cogent Biosciences Inc |
2 Q |
- |
- |
- |
-56.31% |
Collegium Pharmaceutical inc |
2 Q |
54.76% |
9.65% |
9.47% |
-5.78% |
Corcept Therapeutics Inc |
2 Q |
98.66% |
23.24% |
-108.37% |
19.57% |
Coya Therapeutics Inc |
2 Q |
- |
- |
- |
0% |
China Pharma Holdings Inc |
2 Q |
-13.36% |
-54.02% |
-24.14% |
-77.39% |
Cumberland Pharmaceuticals Inc |
2 Q |
86.03% |
7.92% |
17.11% |
-5.02% |
Cannapharmarx Inc |
1 Q |
- |
- |
- |
- |
Catalyst Pharmaceuticals Inc |
2 Q |
87.9% |
37.92% |
30.67% |
36.13% |
Corbus Pharmaceuticals Holdings Inc |
2 Q |
- |
- |
- |
-183.08% |
Cormedix Inc |
2 Q |
- |
- |
- |
-68.87% |
Crinetics Pharmaceuticals Inc |
2 Q |
- |
-5159.82% |
-166.09% |
-61.19% |
Corvus Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-71.23% |
Cti Biopharma Corp |
1 Q |
94.92% |
-55.66% |
-25.75% |
- |
Innovation Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-112.57% |
Catalent Inc |
2 Q |
34.56% |
1.19% |
-23.23% |
8.71% |
Cytomx Therapeutics Inc |
2 Q |
- |
-4.4% |
4.77% |
- |
Citius Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-31.01% |
Cue Biopharma Inc |
2 Q |
- |
-954.05% |
-236.61% |
-95.35% |
Avenir Wellness Solutions Inc |
4 Q |
21.22% |
-806.55% |
-169.3% |
-1323.6% |
Cadrenal Therapeutics Inc |
2 Q |
- |
- |
- |
- |
Cv Sciences Inc |
2 Q |
46.21% |
-34.64% |
26.25% |
45.08% |
Cohbar Inc |
2 Q |
- |
- |
- |
-88.89% |
Celyad Oncology Sa |
4 Q |
- |
- |
- |
-614.13% |
Cyclacel Pharmaceuticals Inc |
2 Q |
- |
-1447.18% |
-340.75% |
-179.85% |
Cyclerion Therapeutics Inc |
1 Q |
- |
- |
- |
-270.55% |
Cytodyn Inc |
2 Q |
- |
- |
- |
- |
Cryoport inc |
2 Q |
43.38% |
-35.7% |
50.47% |
-8.42% |
Cyteir Therapeutics Inc |
2 Q |
- |
- |
- |
-28.93% |
Cytokinetics Incorporated |
2 Q |
- |
-14837.02% |
-3944.87% |
- |
Altamira Therapeutics Ltd |
4 Q |
-372.44% |
-8680.31% |
0% |
- |
Dar Bioscience Inc |
2 Q |
- |
- |
- |
-400.6% |
Day One Biopharmaceuticals Inc |
2 Q |
- |
- |
- |
-7.81% |
Decibel Therapeutics Inc |
2 Q |
- |
- |
- |
-84.03% |
Deciphera Pharmaceuticals Inc |
2 Q |
99.55% |
-126.78% |
-87.27% |
-47.99% |
Journey Medical Corporation |
2 Q |
54.77% |
-48.7% |
-53.1% |
-309.66% |
Diffusion Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-69.97% |
Dice Therapeutics Inc |
2 Q |
- |
- |
- |
-22.01% |
Diamedica Therapeutics Inc |
2 Q |
- |
- |
- |
-43.1% |
Dominari Holdings Inc |
2 Q |
- |
-12201.41% |
-8359.15% |
-36.19% |
Dermata Therapeutics Inc |
2 Q |
- |
- |
- |
-108.55% |
Dicerna Pharmaceuticals Inc |
3 Q |
- |
-27.12% |
-88.09% |
-103.08% |
Durect Corp |
2 Q |
82.75% |
-537.29% |
-362.13% |
-179.02% |
Bright Minds Biosciences Inc |
3 Q |
- |
- |
- |
-141.95% |
Design Therapeutics Inc |
2 Q |
- |
- |
- |
-23.25% |
Dynavax Technologies Corporation |
2 Q |
77.53% |
5.69% |
87.09% |
19.86% |
Dyne Therapeutics Inc |
2 Q |
- |
- |
- |
-79.63% |
Emergent Biosolutions Inc |
2 Q |
43.59% |
-77.33% |
-101.86% |
-48.73% |
Edesa Biotech Inc |
2 Q |
- |
- |
- |
-103.72% |
Effector Therapeutics Inc |
2 Q |
- |
- |
- |
-1125.65% |
Eagle Pharmaceuticals inc |
2 Q |
73.92% |
7.99% |
-10.12% |
4.98% |
Elanco Animal Health Inc |
2 Q |
58.94% |
-9.18% |
4.64% |
-1.35% |
Eledon Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-89.2% |
Elite Pharmaceuticals Inc |
2 Q |
54.29% |
13.05% |
14.26% |
11.12% |
Enliven Therapeutics Inc |
2 Q |
- |
- |
- |
-2.16% |
Eliem Therapeutics Inc |
2 Q |
- |
- |
- |
-36.52% |
Emmaus Life Sciences Inc |
2 Q |
95.28% |
-13.77% |
-3.84% |
- |
Endo International Plc |
2 Q |
57.24% |
4.29% |
-6.41% |
- |
Enlivex Therapeutics Ltd |
4 Q |
- |
- |
- |
-54.64% |
Enochian Biosciences Inc |
1 Q |
- |
- |
- |
-154.69% |
Ensysce Biosciences Inc |
2 Q |
- |
-456.56% |
- |
- |
Enanta Pharmaceuticals Inc |
2 Q |
- |
-206.78% |
- |
-46.77% |
Enveric Biosciences Inc |
2 Q |
- |
- |
- |
-168.47% |
Evolus Inc |
2 Q |
70.19% |
-36.76% |
20.76% |
-556.51% |
Essa Pharma inc |
2 Q |
- |
- |
- |
-17.26% |
Epizyme Inc. |
2 Q |
81.22% |
-129.85% |
-23.09% |
- |
Equillium Inc |
2 Q |
- |
-36.64% |
12.29% |
-62.45% |
Eqrx Inc |
2 Q |
- |
- |
- |
-19.59% |
Erasca Inc |
2 Q |
- |
- |
- |
-59.26% |
Eterna Therapeutics Inc |
2 Q |
- |
- |
- |
-270.22% |
Esperion Therapeutics Inc |
2 Q |
- |
-193.65% |
-24.98% |
- |
89bio Inc |
2 Q |
- |
- |
- |
-39.8% |
Eton Pharmaceuticals Inc |
2 Q |
82.88% |
39.03% |
58.71% |
-1.79% |
Earth Science Tech Inc |
2 Q |
67.64% |
-40.79% |
25.57% |
- |
Entasis Therapeutics Holdings Inc |
1 Q |
- |
- |
- |
-145.48% |
Evofem Biosciences Inc |
2 Q |
6.71% |
-348.17% |
-36.53% |
- |
Evelo Biosciences Inc |
2 Q |
- |
- |
- |
- |
Evotec Se |
4 Q |
23.16% |
-23.38% |
56.24% |
-14.8% |
Evoke Pharma Inc |
2 Q |
- |
-165.1% |
-106.63% |
-258.2% |
Edgewise Therapeutics inc |
2 Q |
- |
- |
- |
-3.16% |
Eyenovia inc |
2 Q |
- |
- |
- |
-158.92% |
Fortress Biotech Inc |
2 Q |
55.33% |
-341.08% |
-377.95% |
-579.62% |
Forte Biosciences Inc |
2 Q |
- |
- |
- |
-68.61% |
Fibrogen Inc |
2 Q |
87.12% |
-197.84% |
-81.15% |
- |
Foghorn Therapeutics Inc |
2 Q |
- |
-526.65% |
28.09% |
- |
Homology Medicines Inc |
2 Q |
- |
-9899.44% |
- |
-80.15% |
Flora Growth Corp |
4 Q |
- |
- |
- |
0% |
Flexion Therapeutics Inc |
3 Q |
82.52% |
-142.14% |
- |
- |
Amicus Therapeutics inc |
2 Q |
90.46% |
-45.8% |
52.28% |
-157.79% |
Frequency Therapeutics Inc |
2 Q |
- |
- |
- |
-107.67% |
F star Therapeutics Inc |
3 Q |
- |
-1636.18% |
-1470.4% |
-56.71% |
Fulcrum Therapeutics Inc |
2 Q |
- |
-2702.61% |
-87.27% |
-39.69% |
First Wave Biopharma Inc |
1 Q |
- |
- |
- |
- |
Galectin Therapeutics Inc |
2 Q |
- |
- |
- |
- |
Gain Therapeutics inc |
2 Q |
- |
- |
- |
-130.19% |
Generation Bio Co |
2 Q |
- |
-3530.23% |
- |
-45.12% |
Global Blood Therapeutics Inc. |
2 Q |
98.03% |
-115.26% |
-182.63% |
-170.37% |
The Greater Cannabis Company Inc |
2 Q |
- |
- |
- |
- |
Geron Corp |
2 Q |
- |
-169748.28% |
-192082.76% |
-84.19% |
Gh Research Plc |
4 Q |
- |
- |
- |
-3.32% |
Guardion Health Sciences Inc |
2 Q |
55.54% |
-52.12% |
-18.17% |
-89.69% |
Galmed Pharmaceuticals Ltd |
4 Q |
- |
- |
- |
133.1% |
Galapagos Nv |
4 Q |
97.61% |
-43.14% |
0% |
-4.09% |
Gelesis Holdings Inc |
2 Q |
55.01% |
-693.86% |
- |
- |
Greenwich Lifesciences Inc |
2 Q |
- |
- |
- |
-49.85% |
Galecto Inc |
2 Q |
- |
- |
- |
-90.21% |
Glycomimetics Inc |
1 Q |
- |
- |
- |
-55.48% |
Generex Biotechnology Corp |
1 Q |
-218.89% |
- |
- |
- |
Genelux Corporation |
2 Q |
- |
- |
- |
- |
Genprex Inc |
2 Q |
- |
- |
- |
-149.6% |
Gossamer Bio Inc |
2 Q |
- |
- |
- |
- |
Geovax Labs Inc |
2 Q |
- |
- |
- |
-78.52% |
Structure Therapeutics Inc |
1 Q |
- |
- |
- |
- |
Gracell Biotechnologies Inc |
4 Q |
- |
- |
- |
-44.16% |
Grifols Sa |
4 Q |
- |
- |
- |
3.21% |
Gri Bio Inc |
2 Q |
- |
- |
- |
-476.51% |
Galera Therapeutics Inc |
2 Q |
- |
- |
- |
- |
Glaxosmithkline Plc |
4 Q |
65.99% |
14.94% |
12.53% |
23.88% |
Globestar Therapeutics Corporation |
2 Q |
- |
- |
- |
- |
Gt Biopharma Inc |
2 Q |
- |
- |
- |
-111.87% |
G1 Therapeutics Inc |
2 Q |
- |
20.55% |
-29.07% |
-143.26% |
Gw Pharmaceuticals Plc |
1 Q |
92.26% |
-12.91% |
-18.79% |
-2.83% |
Hutchmed china Limited |
4 Q |
36.99% |
-84.52% |
-27.92% |
-56.59% |
Hcw Biologics Inc |
2 Q |
19.33% |
-691.13% |
-1756.67% |
-53% |
Hepion Pharmaceuticals inc |
2 Q |
- |
- |
- |
-98.93% |
Humanigen Inc |
1 Q |
- |
-1892.31% |
-3194.12% |
- |
Hillstream Biopharma Inc |
2 Q |
- |
- |
- |
-188.47% |
Hookipa Pharma inc |
2 Q |
- |
-672.49% |
- |
-66.35% |
Hoth Therapeutics Inc |
2 Q |
- |
-120996.83% |
-93649.61% |
-114.51% |
Werewolf Therapeutics Inc |
2 Q |
- |
-63.09% |
-128.83% |
-33.23% |
Inhibitor Therapeutics Inc |
2 Q |
- |
- |
- |
229.02% |
Harmony Biosciences Holdings inc |
2 Q |
81.37% |
25.56% |
21.57% |
47.82% |
Harrow Health Inc |
2 Q |
70.12% |
-12.64% |
10.48% |
-90.85% |
Heron Therapeutics Inc |
2 Q |
36.53% |
-132.42% |
-42.91% |
- |
Hst Global Inc |
2 Q |
- |
- |
- |
- |
Histogen Inc |
2 Q |
- |
-41780% |
-47980% |
-100.61% |
Fsd Pharma Inc |
4 Q |
- |
- |
- |
-77.29% |
Horizon Therapeutics Public Limited Company |
2 Q |
76.8% |
13.46% |
16.21% |
8.54% |
Ibio inc |
2 Q |
- |
- |
- |
-260.14% |
Intercept Pharmaceuticals inc |
2 Q |
99.78% |
-7% |
88.79% |
248.75% |
Ideaya Biosciences Inc |
2 Q |
- |
-787.98% |
- |
-19.09% |
Inflarx N v |
4 Q |
- |
- |
- |
-33.37% |
Igc Pharma Inc |
2 Q |
45.95% |
-373.87% |
-265.41% |
-64.87% |
Igm Biosciences Inc |
2 Q |
- |
- |
- |
-84.19% |
Intelgenx Technologies Corp |
1 Q |
-191.36% |
-1804.94% |
- |
- |
I mab |
4 Q |
- |
- |
- |
-86.16% |
Immunogen inc |
2 Q |
- |
-5.11% |
- |
-76.92% |
Imago Biosciences Inc |
3 Q |
- |
- |
- |
-13.66% |
Immutep Ltd |
2 Q |
- |
-753.57% |
- |
-40.81% |
Immix Biopharma Inc |
4 Q |
- |
- |
- |
-48.64% |
Immunome Inc |
1 Q |
- |
-180.63% |
- |
-135.42% |
Imunon Inc |
2 Q |
- |
- |
- |
-102.76% |
Impel Pharmaceuticals Inc |
2 Q |
52.86% |
-115.6% |
-319.03% |
- |
Immuron Limited |
2 Q |
88.43% |
-255.78% |
- |
-19.3% |
Immuneering Corporation |
2 Q |
- |
- |
- |
-46.67% |
Immune Therapeutics Inc |
2 Q |
- |
- |
- |
- |
Immunic Inc |
2 Q |
- |
- |
- |
-132.61% |
Integrated Biopharma Inc |
2 Q |
7.96% |
0.32% |
-9.8% |
-0.18% |
Intercure Ltd |
4 Q |
39.9% |
11.26% |
9.75% |
8.39% |
Indaptus Therapeutics Inc |
2 Q |
- |
- |
- |
-63.55% |
Infinity Pharmaceuticals Inc |
2 Q |
- |
-1707.72% |
- |
- |
Inmed Pharmaceuticals Inc |
2 Q |
31.15% |
78.14% |
-19.42% |
-103.14% |
Insmed Inc |
2 Q |
78.84% |
-312.2% |
-454.04% |
- |
Innoviva Inc |
1 Q |
97.96% |
44.39% |
-187.18% |
37.23% |
Inozyme Pharma Inc |
2 Q |
- |
- |
- |
-58.78% |
Io Biotech Inc |
2 Q |
- |
- |
- |
-56.79% |
Ionis Pharmaceuticals Inc |
1 Q |
98.97% |
-95.25% |
24.94% |
-52.07% |
Immunoprecise Antibodies Ltd |
1 Q |
55.95% |
-128.53% |
0% |
-45.95% |
Intellipharmaceutics International Inc |
4 Q |
- |
-4400.55% |
- |
- |
Disc Medicine Inc |
2 Q |
- |
- |
- |
-28.57% |
Ironwood Pharmaceuticals inc |
1 Q |
- |
39.78% |
-27.44% |
122.32% |
International Stem Cell Corporation |
2 Q |
61.27% |
14.07% |
23.85% |
- |
Iveric Bio Inc |
1 Q |
- |
- |
- |
-57% |
Intra cellular Therapies Inc |
2 Q |
- |
-38.62% |
60.05% |
-28.63% |
Iterum Therapeutics Plc |
2 Q |
- |
- |
- |
-260.09% |
Inventiva S a |
4 Q |
- |
-445.64% |
- |
-109.15% |
Jaguar Health inc |
2 Q |
81.65% |
-459.3% |
-214.5% |
-1157.69% |
Janux Therapeutics Inc |
2 Q |
- |
-1656.39% |
- |
-21.45% |
Jazz Pharmaceuticals Plc |
2 Q |
- |
10.91% |
11.95% |
-5.9% |
Johnson and Johnson |
3 Q |
67.19% |
18.74% |
1.56% |
25.57% |
Kineta Inc |
2 Q |
- |
7.27% |
-28.44% |
-1657.39% |
Kala Bio inc |
2 Q |
- |
- |
- |
-58.6% |
Kalvista Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-60.57% |
Kyto Technology And Life Science Inc |
4 Q |
- |
- |
- |
13.86% |
Kadmon holdings inc |
3 Q |
95.63% |
-232.46% |
47.23% |
-216.92% |
Chinook Therapeutics Inc |
2 Q |
- |
-6641.27% |
- |
-58.28% |
Kindred Biosciences Inc |
2 Q |
81.93% |
-258.07% |
- |
-54.55% |
Kamada Ltd |
4 Q |
29.26% |
-2.15% |
0% |
-1.26% |
Kiniksa Pharmaceuticals Ltd |
2 Q |
89.23% |
20.95% |
44.7% |
58.48% |
Kinnate Biopharma Inc |
2 Q |
- |
- |
- |
-57.01% |
Kiora Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-105.85% |
Karyopharm Therapeutics Inc |
2 Q |
96.82% |
-86.83% |
-9.83% |
- |
Kronos Bio Inc |
2 Q |
- |
-1595.55% |
- |
-51.01% |
Keros Therapeutics Inc |
2 Q |
- |
- |
- |
-42.19% |
Karuna Therapeutics Inc |
2 Q |
- |
- |
- |
-27.13% |
Kintara Therapeutics Inc |
2 Q |
- |
- |
- |
-282.78% |
Pasithea Therapeutics Corp |
2 Q |
- |
- |
- |
-41.47% |
Kura Oncology Inc |
2 Q |
- |
- |
- |
-33.01% |
Khosla Ventures Acquisition Co |
2 Q |
- |
- |
- |
- |
Kazia Therapeutics Limited |
2 Q |
- |
-55.46% |
57.71% |
-22.25% |
Kezar Life Sciences Inc |
2 Q |
- |
- |
- |
-31.81% |
Landos Biopharma Inc |
2 Q |
- |
- |
- |
3.75% |
Longboard Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-74.91% |
4d Pharma Plc |
4 Q |
- |
-4448.19% |
- |
-98.53% |
Lannett Company Inc |
1 Q |
19.1% |
-127.69% |
-11.72% |
- |
Legend Biotech Corporation |
4 Q |
- |
-430.12% |
- |
-81.96% |
Lexaria Bioscience Corp |
2 Q |
86.32% |
-2558.85% |
-116.15% |
-194.81% |
Lifevantage Corp |
2 Q |
80.16% |
3.65% |
3.86% |
7.7% |
Ligand Pharmaceuticals Incorporated |
2 Q |
67.61% |
8.69% |
-228.64% |
3.99% |
Longeveron Inc |
1 Q |
81.08% |
-948.65% |
-952.97% |
-11.82% |
Lianbio |
2 Q |
- |
- |
- |
-0.1% |
Lftd Partners Inc |
2 Q |
45.01% |
13.25% |
-11.35% |
7.12% |
Lipella Pharmaceuticals Inc |
2 Q |
- |
-1442.39% |
-848.47% |
- |
Lixte Biotechnology Holdings Inc |
2 Q |
- |
- |
- |
-133.96% |
Eli Lilly And Company |
2 Q |
78.26% |
21.21% |
-10.24% |
59.9% |
Liminal Biosciences Inc |
4 Q |
- |
- |
- |
36.05% |
Landec Corporation |
1 Q |
26.27% |
-24.29% |
1.44% |
-36.52% |
Lipocine Inc |
2 Q |
- |
-12925.26% |
- |
-36.05% |
Leap Therapeutics inc |
2 Q |
- |
- |
- |
-136.66% |
Liquidia Corporation |
2 Q |
85.98% |
-491.37% |
-129.88% |
-62.1% |
Larimar Therapeutics Inc |
2 Q |
- |
- |
- |
-29.96% |
Lucy Scientific Discovery Inc |
1 Q |
- |
- |
- |
- |
Lantern Pharma Inc |
2 Q |
- |
- |
- |
-26.42% |
Lumos Pharma Inc |
2 Q |
- |
-1694.69% |
-1171.92% |
-56.88% |
Lexicon Pharmaceuticals Inc |
2 Q |
97.48% |
-14165.3% |
- |
-97.63% |
Lyell Immunopharma Inc |
2 Q |
- |
-236629.63% |
- |
-26.4% |
Merrimack Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-17.14% |
Maia Biotechnology Inc |
2 Q |
- |
- |
- |
-65.5% |
Marizyme Inc |
1 Q |
69.55% |
-1980.7% |
-140.38% |
-120.38% |
Mustang Bio inc |
1 Q |
- |
- |
- |
-87.26% |
Moleculin Biotech Inc |
2 Q |
- |
- |
- |
-59.57% |
Seres Therapeutics Inc |
2 Q |
- |
36.81% |
- |
-1155.47% |
Madrigal Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-285.72% |
Medicenna Therapeutics Corp. |
1 Q |
- |
- |
- |
- |
23andme Holding Co |
2 Q |
50.56% |
-172.42% |
-119.48% |
-44.16% |
Mei Pharma Inc |
2 Q |
- |
-688.33% |
- |
-88.04% |
Macrogenics Inc |
2 Q |
98.04% |
- |
-879.31% |
5.46% |
Magenta Therapeutics Inc |
2 Q |
- |
- |
- |
-71.92% |
Mirum Pharmaceuticals Inc |
2 Q |
- |
-197.45% |
- |
-132.79% |
Milestone Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-98.76% |
Stealth Biotherapeutics Corp |
4 Q |
- |
- |
- |
- |
Moonlake Immunotherapeutics |
2 Q |
- |
- |
- |
-38.87% |
Mineralys Therapeutics Inc |
1 Q |
- |
- |
- |
- |
Mallinckrodt Plc |
1 Q |
35.81% |
-24.37% |
4.18% |
-48.65% |
Mannkind Corporation |
2 Q |
81.46% |
-10.83% |
0.65% |
- |
Medicinova Inc |
2 Q |
- |
- |
- |
-18.02% |
Monopar Therapeutics Inc |
2 Q |
- |
- |
- |
-100.87% |
Morphosys Ag |
4 Q |
82.08% |
-286.43% |
61.13% |
-210.09% |
Morphic Holding inc |
2 Q |
- |
- |
- |
-27.71% |
Medicure Inc |
4 Q |
69.69% |
5.92% |
11.78% |
6.5% |
Mereo Biopharma Group Plc |
4 Q |
- |
- |
- |
20.57% |
Merck and Co Inc |
1 Q |
66.17% |
27.12% |
2.81% |
38.23% |
Marker Therapeutics inc |
2 Q |
- |
- |
- |
-68.58% |
Marinus Pharmaceuticals Inc |
2 Q |
93.65% |
-525.14% |
-314.37% |
-32.53% |
Mersana Therapeutics inc |
2 Q |
- |
-509.73% |
55.44% |
-255.91% |
Mirati Therapeutics Inc |
2 Q |
- |
-1292.28% |
-818.55% |
-79.37% |
Merus N v |
2 Q |
- |
-305.78% |
-14.13% |
-69.89% |
Maravai Lifesciences Holdings Inc |
2 Q |
37.21% |
-17.33% |
-75.4% |
19.61% |
Musclepharm Corporation |
1 Q |
11.52% |
-48.1% |
-5.26% |
- |
Metacrine Inc |
3 Q |
- |
- |
- |
-83.77% |
Molecular Templates inc |
2 Q |
- |
- |
-1302.34% |
- |
Matinas Biopharma Holdings Inc |
2 Q |
- |
- |
- |
-58.38% |
Murphy Canyon Acquisition Corp |
2 Q |
- |
- |
- |
- |
Mainz Biomed N v |
4 Q |
34.38% |
-4979.9% |
0% |
-187.2% |
Myovant Sciences Ltd |
4 Q |
92.6% |
-57.5% |
-95.85% |
- |
Innovation1 Biotech Inc |
2 Q |
- |
- |
- |
-2398.21% |
Nature s Sunshine Products inc |
2 Q |
73.19% |
2.32% |
2.81% |
4.25% |
Nascent Biotech Inc |
2 Q |
- |
-2572495.24% |
-774790.48% |
- |
Nabriva Therapeutics Plc |
1 Q |
41.53% |
-114.62% |
-139.87% |
-365.53% |
Neubase Therapeutics inc |
1 Q |
- |
- |
- |
-119.35% |
Nanobiotix S a |
4 Q |
- |
-1194.33% |
- |
- |
Novabay Pharmaceuticals Inc |
1 Q |
60.25% |
-4.41% |
-86.88% |
-36.44% |
Nucana Plc |
4 Q |
- |
- |
- |
-105.28% |
Neptune Wellness Solutions Inc |
2 Q |
26.45% |
-60.22% |
-5.77% |
- |
Minerva Neurosciences Inc |
2 Q |
- |
- |
- |
- |
Neximmune Inc |
2 Q |
- |
- |
- |
-161.71% |
Ngm Biopharmaceuticals Inc |
2 Q |
- |
-2688.76% |
-1003.37% |
-70.78% |
Nighthawk Biosciences inc |
2 Q |
41.67% |
-2122.56% |
-302.55% |
-79.5% |
Nektar Therapeutics |
2 Q |
65.88% |
-249.39% |
-127.94% |
-100.89% |
Nkarta Inc |
2 Q |
- |
- |
- |
-34.82% |
Nls Pharmaceutics Ltd |
4 Q |
- |
- |
- |
-502.79% |
Neoleukin Therapeutics Inc |
1 Q |
- |
- |
- |
-36.77% |
9 Meters Biopharma Inc |
1 Q |
- |
- |
- |
-584.98% |
Nanomix Corp |
4 Q |
- |
- |
- |
- |
Nanoviricides inc |
1 Q |
- |
- |
- |
-32.87% |
Novan Inc |
1 Q |
59.41% |
-445.96% |
-5.62% |
-616.76% |
Neurobo Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-60.64% |
Nurix Therapeutics Inc |
2 Q |
- |
-79.14% |
82.76% |
-53.36% |
Nrx Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-740.89% |
Rebus Holdings Inc |
2 Q |
- |
- |
- |
- |
Intec Pharma Ltd |
1 Q |
- |
- |
- |
-96.37% |
Nuvation Bio Inc |
2 Q |
- |
- |
- |
-13.97% |
Nuvalent Inc |
2 Q |
- |
- |
- |
-25.6% |
Nuvectis Pharma inc |
1 Q |
- |
- |
- |
- |
Novartis Ag |
4 Q |
70.12% |
13.42% |
23.94% |
11.7% |
Northwest Biotherapeutics inc |
2 Q |
- |
-7446.27% |
-2371.64% |
- |
Nexien Biopharma Inc |
1 Q |
- |
- |
- |
- |
Nextcure Inc |
2 Q |
- |
- |
- |
-43.74% |
Theralink Technologies Inc |
2 Q |
75.26% |
- |
-90.31% |
- |
Obseva Sa |
4 Q |
- |
-290.25% |
- |
-180.52% |
Obseva Sa |
4 Q |
- |
-107.3% |
-255.45% |
0% |
Ocean Biomedical Inc |
1 Q |
- |
- |
- |
- |
Oculis Holding Ag |
4 Q |
- |
-4243.2% |
0% |
- |
Ocular Therapeutix Inc |
2 Q |
91.41% |
-136.19% |
-81.79% |
-384.42% |
Ocuphire Pharma Inc |
2 Q |
- |
-135.03% |
26.92% |
54.45% |
Odonate Therapeutics Inc |
3 Q |
- |
- |
- |
-102.72% |
Oragenics Inc |
2 Q |
- |
-23175.46% |
- |
-104.87% |
Organon and Co |
2 Q |
60.2% |
15.05% |
-8.27% |
- |
Olema Pharmaceuticals inc |
2 Q |
- |
- |
- |
-51.76% |
Omeros Corporation |
2 Q |
- |
- |
- |
140.34% |
Oncorus Inc |
1 Q |
- |
- |
- |
-134.31% |
Oncosec Medical Incorporated |
4 Q |
- |
- |
- |
-868.37% |
Oncternal Therapeutics Inc |
2 Q |
- |
-8458.49% |
- |
-75.67% |
Oncolytics Biotech Inc |
4 Q |
- |
- |
- |
-93.71% |
Onconova Therapeutics inc |
1 Q |
- |
-10312.5% |
-8101.79% |
-61.68% |
Opko Health Inc |
2 Q |
57.42% |
-7.4% |
-1.03% |
-13.33% |
Opiant Pharmaceuticals Inc |
3 Q |
- |
-5703.35% |
-2759.19% |
-97.18% |
Optinose Inc |
2 Q |
86.78% |
13.23% |
-64.86% |
- |
Organogenesis Holdings Inc |
2 Q |
77.57% |
4.53% |
0.08% |
3.42% |
Orgenesis Inc |
2 Q |
53.66% |
52.49% |
-36.17% |
37.77% |
Oric Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-40.74% |
Oramed Pharmaceuticals Inc |
2 Q |
- |
- |
-2572.26% |
15.32% |
Orphazyme A |
4 Q |
- |
-1731.11% |
- |
-100.97% |
Otonomy Inc |
3 Q |
- |
- |
- |
-137.86% |
Oncotelic Therapeutics Inc |
2 Q |
- |
- |
- |
-91.82% |
Ovid Therapeutics Inc |
2 Q |
- |
-16544.44% |
- |
-38.92% |
One World Products Inc |
2 Q |
-76% |
-759800% |
- |
- |
Phibro Animal Health Corporation |
2 Q |
30.14% |
4.52% |
1.59% |
12.01% |
Prestige Consumer Healthcare Inc |
2 Q |
55.5% |
43.77% |
-1.4% |
-5.55% |
Panbela Therapeutics Inc |
2 Q |
- |
- |
- |
- |
Puma Biotechnology Inc |
2 Q |
78.27% |
3.9% |
-2.54% |
-9.76% |
Rapid Therapeutic Science Laboratories Inc |
2 Q |
- |
- |
- |
- |
Pacira Biosciences inc |
2 Q |
71.55% |
15.2% |
30.25% |
-0.59% |
Processa Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-233.27% |
Procyon Corporation |
2 Q |
77.94% |
0.62% |
10.61% |
-1.91% |
Pds Biotechnology Corp |
2 Q |
- |
- |
- |
-116.12% |
Pepgen Inc |
2 Q |
- |
- |
- |
-40.53% |
Pfizer Inc |
1 Q |
61.09% |
30.67% |
2.06% |
32.65% |
Precigen Inc |
2 Q |
3.96% |
-1149.92% |
-395.81% |
14.31% |
Pharming Group N v |
4 Q |
91.46% |
6.65% |
99.77% |
7.82% |
Phasebio Pharmaceuticals Inc. |
2 Q |
- |
-8012.02% |
-5232.69% |
- |
Phathom Pharmaceuticals Inc |
2 Q |
- |
- |
- |
- |
Phio Pharmaceuticals Corp |
2 Q |
- |
- |
- |
-119.85% |
Pharvaris N v |
4 Q |
- |
- |
- |
-28.63% |
Pieris Pharmaceuticals Inc |
2 Q |
- |
19.83% |
25.91% |
-90.41% |
Peak Pharmaceuticals Inc |
4 Q |
- |
- |
- |
- |
Protokinetix Incorporated |
2 Q |
- |
- |
- |
-499.85% |
Pliant Therapeutics Inc |
2 Q |
- |
-16609.68% |
-19183.87% |
-33.1% |
Plx Pharma Inc |
3 Q |
-278.24% |
-2201.3% |
-2563.73% |
-114.93% |
Priveterra Acquisition Corp |
2 Q |
- |
- |
- |
- |
Promis Neurosciences inc |
2 Q |
- |
- |
- |
- |
Pmv Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-31.05% |
Point Biopharma Global Inc |
2 Q |
- |
-522.23% |
-1106.61% |
22.69% |
Purple Biotech Ltd |
4 Q |
- |
- |
- |
46.2% |
Propanc Biopharma Inc |
1 Q |
- |
- |
- |
- |
Praxis Precision Medicines Inc |
2 Q |
- |
-4393.34% |
- |
-178.6% |
Pardes Biosciences Inc |
2 Q |
- |
- |
- |
-43.36% |
Painreform Ltd |
4 Q |
- |
- |
- |
-40.07% |
Perrigo Company Plc |
1 Q |
31.46% |
-0.22% |
8.03% |
2.85% |
Prelude Therapeutics Inc |
3 Q |
- |
- |
- |
10.79% |
Procaps Group S a |
4 Q |
58.44% |
10.38% |
0% |
- |
Prophase Labs Inc |
2 Q |
51.8% |
-27.63% |
-46.51% |
-6.97% |
Proqr Therapeutics N v |
4 Q |
- |
- |
- |
0% |
Prothena Corporation Public Limited Company |
2 Q |
- |
-1358.42% |
- |
-25.43% |
Puretech Health Plc |
4 Q |
- |
-237.32% |
- |
-6.77% |
Paratek Pharmaceuticals Inc |
1 Q |
80.01% |
-64.49% |
34.51% |
- |
Provention Bio Inc |
4 Q |
- |
-307.75% |
-539.56% |
-103.36% |
Ptc Therapeutics inc |
1 Q |
- |
-63.05% |
-28.28% |
- |
Protagonist Therapeutics inc |
2 Q |
- |
- |
- |
-56.78% |
Protagenic Therapeutics Inc new |
4 Q |
- |
- |
- |
-45.47% |
Palatin Technologies Inc |
2 Q |
- |
-608.11% |
-660.79% |
-319.15% |
Petros Pharmaceuticals inc |
1 Q |
78.13% |
-55.01% |
-43.93% |
- |
Pulmatrix Inc |
4 Q |
- |
-246.84% |
-1066.28% |
-51.13% |
Provectus Biopharmaceuticals Inc |
2 Q |
- |
-515.97% |
23.3% |
- |
Paxmedica Inc |
3 Q |
- |
- |
- |
- |
Pyxis Oncology Inc |
2 Q |
- |
- |
- |
-61.15% |
Q Biomed inc |
1 Q |
- |
- |
- |
- |
Qualigen Therapeutics Inc |
2 Q |
- |
-215.59% |
-182.95% |
-236.35% |
Qilian International Holding Group Limited |
3 Q |
9.6% |
2.11% |
1.14% |
2.49% |
Uniqure N v |
2 Q |
- |
-2827.17% |
- |
-44.91% |
Rain Oncology Inc |
2 Q |
- |
- |
- |
-91.93% |
Rani Therapeutics Holdings Inc |
2 Q |
- |
- |
- |
-102.15% |
Rapt Therapeutics Inc |
2 Q |
- |
- |
- |
-46.21% |
Ultragenyx Pharmaceutical Inc |
2 Q |
90.85% |
-147.57% |
14.9% |
-246.23% |
Rasna Therapeutics Inc |
2 Q |
- |
- |
- |
- |
Rocket Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-57.83% |
Arcus Biosciences Inc |
2 Q |
- |
-258.62% |
-27.59% |
-45.58% |
Redhill Biopharma Ltd |
4 Q |
46.06% |
- |
47.4% |
- |
Radius Health inc. |
2 Q |
90.43% |
-21.85% |
1.5% |
- |
Dr Reddy s Laboratories Limited |
1 Q |
56.65% |
18.32% |
0% |
19.5% |
Regeneron Pharmaceuticals Inc |
2 Q |
93.91% |
30.66% |
-62.67% |
18.77% |
Reata Pharmaceuticals Inc |
2 Q |
- |
- |
-158.7% |
- |
Revelation Biosciences Inc |
2 Q |
- |
- |
- |
37.76% |
Regen Biopharma Inc |
2 Q |
- |
-313.58% |
-274.99% |
- |
Regulus Therapeutics Inc |
1 Q |
- |
- |
- |
-77.06% |
Regenerx Biopharmaceuticals inc |
1 Q |
- |
-2007.3% |
-986.62% |
- |
Rigel Pharmaceuticals Inc |
2 Q |
96% |
-24.55% |
31.72% |
- |
Relmada Therapeutics Inc |
2 Q |
- |
- |
- |
-94.92% |
Rallybio Corporation |
2 Q |
- |
- |
- |
-47.35% |
Rockwell Medical inc |
4 Q |
-14.88% |
-59.68% |
-67.48% |
-225.3% |
Avidity Biosciences Inc |
2 Q |
- |
-2030.44% |
- |
-37.33% |
Transcode Therapeutics Inc |
2 Q |
- |
- |
- |
-557.17% |
Renovorx Inc |
2 Q |
- |
- |
- |
-210.63% |
Roivant Sciences Ltd |
2 Q |
- |
-1516.12% |
-1121.29% |
-74.08% |
Reneo Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-56.76% |
Royalty Pharma Plc |
2 Q |
55.18% |
65.28% |
36.68% |
4.76% |
Repare Therapeutics Inc |
2 Q |
- |
-39.49% |
-19.56% |
-1.14% |
Respirerx Pharmaceuticals Inc |
2 Q |
- |
- |
- |
- |
Rvl Pharmaceuticals Plc |
2 Q |
86.32% |
-326.71% |
-184.37% |
-155.18% |
Revance Therapeutics Inc |
2 Q |
69.71% |
-115.8% |
7.84% |
-5.14% |
Reviva Pharmaceuticals Holdings Inc |
2 Q |
- |
- |
- |
-306.16% |
Prometheus Biosciences Inc |
1 Q |
- |
-3699.19% |
-19388.87% |
-33.5% |
Rhythm Pharmaceuticals inc |
2 Q |
88.37% |
-242.98% |
31.34% |
-84.39% |
Rezolute Inc |
2 Q |
- |
- |
- |
-38.51% |
Sage Therapeutics Inc |
2 Q |
91.71% |
-6480.4% |
-3438.88% |
-49.82% |
Cassava Sciences Inc |
2 Q |
- |
- |
- |
-44.48% |
Strongbridge Biopharma plc |
2 Q |
95.35% |
-131.86% |
-100.82% |
-66.82% |
Sunshine Biopharma Inc |
2 Q |
35.12% |
-16.22% |
0.37% |
-94.77% |
Scpharmaceuticals Inc |
2 Q |
78.39% |
-864.1% |
-250.49% |
-73.77% |
Scopus Biopharma Inc |
2 Q |
- |
- |
- |
- |
Societal Cdmo Inc |
2 Q |
20.51% |
-14.73% |
-7.29% |
-39.72% |
Scynexis Inc |
2 Q |
- |
93.01% |
23.87% |
212.29% |
Schrodinger Inc |
2 Q |
39.25% |
12.16% |
- |
12.56% |
Seelos Therapeutics inc |
2 Q |
- |
-7039.62% |
-1960.86% |
- |
Selecta Biosciences Inc |
2 Q |
- |
-216.94% |
-238.54% |
-43.98% |
Sangui Biotech International Inc |
1 Q |
- |
-205.74% |
-12.47% |
- |
Sagimet Biosciences inc |
2 Q |
- |
- |
- |
- |
Sigilon Therapeutics Inc |
2 Q |
- |
-127.22% |
-366.66% |
-83.83% |
Shuttle Pharmaceuticals Holdings Inc |
2 Q |
- |
- |
- |
-81.04% |
Siga Technologies Inc |
2 Q |
83.42% |
-48.92% |
-671.42% |
18.07% |
Sio Gene Therapies Inc |
4 Q |
- |
- |
- |
-55.94% |
Skinvisible Inc |
2 Q |
- |
-5521.5% |
-511.8% |
- |
Skye Bioscience Inc |
2 Q |
- |
- |
- |
- |
Sol gel Technologies Ltd |
4 Q |
- |
10.3% |
41.45% |
5.79% |
Silence Therapeutics Plc |
4 Q |
39.94% |
-317.44% |
- |
-462.23% |
Acelyrin Inc |
1 Q |
- |
- |
- |
- |
Salarius Pharmaceuticals inc |
2 Q |
- |
- |
- |
-292.88% |
Sellas Life Sciences Group Inc |
2 Q |
- |
- |
- |
-406.99% |
Summit Therapeutics Inc |
2 Q |
- |
- |
- |
-466.06% |
Syndax Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-39.08% |
Soligenix inc |
2 Q |
11.07% |
-779.02% |
- |
-7335.81% |
Sonoma Pharmaceuticals Inc |
2 Q |
35.13% |
-41.38% |
-8.05% |
-81.76% |
Synaptogenix Inc |
2 Q |
- |
- |
- |
40.31% |
Sensei Biotherapeutics Inc |
2 Q |
- |
- |
- |
-46.2% |
Sanofi |
4 Q |
69.83% |
18.69% |
22.25% |
11.29% |
Sonnet Biotherapeutics Holdings Inc |
2 Q |
- |
-10710.29% |
-11856.46% |
-4385.1% |
Spectrum Pharmaceuticals Inc |
1 Q |
93.19% |
-32.07% |
76.88% |
-209.59% |
Spruce Biosciences Inc |
2 Q |
- |
-592.33% |
- |
-54.8% |
Scisparc Ltd |
4 Q |
76.1% |
- |
- |
40.19% |
Spero Therapeutics Inc |
2 Q |
- |
-438.66% |
-683.51% |
-17.69% |
Ars Pharmaceuticals Inc |
2 Q |
- |
-173700% |
- |
-8.75% |
Sarepta Therapeutics Inc |
2 Q |
- |
-9.16% |
-7.56% |
-159.95% |
Sierra Oncology Inc |
1 Q |
- |
- |
- |
-76.49% |
Statera Biopharma Inc fka Cytocom Inc |
3 Q |
74.74% |
-500.68% |
0% |
- |
Stoke Therapeutics Inc |
2 Q |
- |
- |
- |
-52.95% |
Satsuma Pharmaceuticals Inc |
1 Q |
- |
- |
- |
-115.24% |
Shattuck Labs Inc |
2 Q |
- |
-10673% |
- |
-54.86% |
Supernus Pharmaceuticals inc |
2 Q |
84.44% |
-0.61% |
-322.72% |
4.86% |
Sunwin Stevia International Inc. |
2 Q |
14.99% |
-2.52% |
8.06% |
-106.36% |
Sinovac Biotech Ltd |
4 Q |
54.15% |
5.9% |
- |
0.69% |
Savara Inc |
2 Q |
- |
- |
- |
-41.62% |
60 Degrees Pharmaceuticals Inc |
2 Q |
-209.04% |
-5616.46% |
-412.88% |
- |
Synlogic Inc |
2 Q |
- |
-42994.29% |
- |
-85.18% |
Syros Pharmaceuticals Inc |
2 Q |
- |
-1279.84% |
- |
-87.04% |
Takeda Pharmaceutical Company Limited |
1 Q |
69.11% |
7.87% |
20.57% |
4.99% |
Taro Pharmaceutical Industries Ltd |
1 Q |
46.83% |
4.44% |
16.03% |
1.47% |
Theravance Biopharma inc |
2 Q |
- |
-113.79% |
-596.91% |
220.85% |
Tricida Inc |
3 Q |
- |
- |
- |
- |
Alaunos Therapeutics Inc |
2 Q |
- |
-219325% |
-477925% |
-120.93% |
Tenax Therapeutics Inc |
2 Q |
- |
- |
- |
96.87% |
Terns Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-28.19% |
Teva Pharmaceutical Industries Limited |
2 Q |
46.31% |
-23.16% |
29.71% |
-27% |
Tff Pharmaceuticals Inc |
2 Q |
- |
-1505.98% |
-1365.94% |
-153.67% |
Tg Therapeutics inc |
2 Q |
- |
-296.19% |
- |
-309.59% |
Third Harmonic Bio Inc |
2 Q |
- |
- |
- |
5.8% |
Thorne Healthtech Inc |
2 Q |
55.89% |
5.96% |
0.87% |
13.58% |
Theseus Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-25.55% |
Teligent Inc |
2 Q |
-25.91% |
-123.32% |
-47.14% |
- |
Tiziana Life Sciences Ltd |
4 Q |
- |
- |
- |
-78.67% |
Timber Pharmaceuticals Inc |
2 Q |
- |
-29367.95% |
-19196.18% |
-516.88% |
Tango Therapeutics Inc |
2 Q |
- |
-141.87% |
60.28% |
-44.38% |
Tonix Pharmaceuticals Holding Corp |
1 Q |
- |
- |
- |
-48.46% |
Theriva Biologics inc |
1 Q |
- |
- |
- |
-31.89% |
Tempest Therapeutics Inc |
2 Q |
- |
- |
- |
-218.64% |
Turning Point Therapeutics Inc. |
2 Q |
- |
-103435.29% |
-16289.92% |
-37.45% |
Entrada Therapeutics Inc |
2 Q |
- |
-76.21% |
-814.01% |
-30.45% |
Trillium Therapeutics Inc |
3 Q |
- |
- |
- |
15.79% |
Trevi Therapeutics Inc |
2 Q |
- |
- |
- |
-26.38% |
Trevena inc |
2 Q |
97.09% |
-265.21% |
-25.39% |
-265.73% |
2seventy Bio Inc |
2 Q |
97.48% |
-116.76% |
-270.24% |
-51.38% |
Travere Therapeutics Inc |
2 Q |
96.67% |
-143.44% |
-151.6% |
-273.8% |
Therapeuticsmd Inc |
2 Q |
- |
-552.4% |
-805.26% |
341.13% |
Neuropathix Inc. |
1 Q |
- |
-767.19% |
41.6% |
- |
Tyme Technologies Inc. |
2 Q |
- |
- |
- |
-29.11% |
Tyra Biosciences Inc |
2 Q |
- |
- |
- |
-19.96% |
Unity Biotechnology Inc |
2 Q |
- |
- |
- |
-76.08% |
Unicycive Therapeutics Inc |
2 Q |
- |
- |
- |
- |
Universe Pharmaceuticals Inc |
3 Q |
54.53% |
-21.76% |
-5.9% |
-18.81% |
Urogen Pharma Ltd |
2 Q |
90.34% |
-116.62% |
-79.3% |
- |
United Therapeutics Corporation |
2 Q |
89.25% |
43.45% |
-16.13% |
17.52% |
Vaccitech Plc |
2 Q |
- |
-7132.93% |
-5478.44% |
-23.44% |
Avricore Health Inc |
4 Q |
25.83% |
-46.27% |
17.12% |
-41.66% |
Vaxxinity Inc |
2 Q |
- |
- |
- |
-129% |
Vbi Vaccines Inc |
2 Q |
- |
-6198.33% |
-2715.56% |
-235.41% |
Vascular Biogenics Ltd |
2 Q |
- |
- |
- |
234.43% |
Vaccinex Inc |
2 Q |
- |
- |
- |
0% |
Vera Therapeutics Inc |
2 Q |
- |
- |
- |
-89.3% |
Veru Inc |
2 Q |
38.09% |
- |
-225.51% |
-243.8% |
Verve Therapeutics Inc |
2 Q |
- |
-2579.22% |
-654.75% |
-37.08% |
Viveon Health Acquisition Corp |
4 Q |
- |
- |
- |
- |
Vincerx Pharma Inc |
2 Q |
- |
- |
- |
-134.99% |
Virios Therapeutics inc |
1 Q |
- |
- |
- |
-36.07% |
Viracta Therapeutics Inc |
2 Q |
- |
- |
- |
-133.85% |
Viking Therapeutics Inc |
2 Q |
- |
- |
- |
-36.28% |
Vanda Pharmaceuticals Inc |
2 Q |
92.4% |
3.3% |
-443.24% |
2.81% |
Verrica Pharmaceuticals Inc |
2 Q |
- |
-6038.46% |
-2643.96% |
-45.7% |
Verona Pharma Plc |
2 Q |
- |
- |
- |
-20.3% |
Virpax Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-96.12% |
Vertex Pharmaceuticals Inc |
2 Q |
87.62% |
36.73% |
34.41% |
23.68% |
Verastem Inc |
2 Q |
- |
- |
- |
-122.33% |
Vistagen Therapeutics Inc |
2 Q |
- |
- |
- |
-268.03% |
Viatris Inc |
2 Q |
41.05% |
6.74% |
3.08% |
9.04% |
Vtv Therapeutics Inc |
2 Q |
- |
- |
- |
- |
Ventyx Biosciences Inc |
2 Q |
- |
- |
- |
-43.95% |
Vyne Therapeutics Inc |
2 Q |
- |
-7450.37% |
-7095.56% |
-122.06% |
Wellness Center Usa Inc |
2 Q |
90.33% |
-689.92% |
-20.87% |
- |
Wave Life Sciences Ltd |
2 Q |
- |
-95.47% |
-160.95% |
- |
Xenetic Biosciences Inc |
2 Q |
- |
-161.44% |
-194.95% |
-31.71% |
Xbiotech Inc |
2 Q |
- |
- |
- |
-11.95% |
Exicure Inc |
2 Q |
- |
- |
- |
34.49% |
Xenon Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-23.3% |
Xeris Biopharma Holdings Inc |
1 Q |
83.98% |
-101.42% |
-213.83% |
-63.96% |
Xilio Therapeutics inc |
2 Q |
- |
- |
- |
-87.74% |
Xencor Inc |
2 Q |
- |
-48.23% |
-82.78% |
-18.13% |
Xoma Corporation |
2 Q |
- |
-325.69% |
-775.33% |
-25.75% |
Xortx Therapeutics Inc |
4 Q |
- |
-697.75% |
72.33% |
-9.87% |
Novaccess Global Inc |
1 Q |
- |
- |
- |
- |
Xtl Biopharmaceuticals Ltd |
4 Q |
- |
- |
- |
-19.55% |
Y mabs Therapeutics inc |
1 Q |
82.54% |
-267.67% |
-236.89% |
-59.67% |
Ys Biopharma Co Ltd |
1 Q |
77.68% |
-21.17% |
0% |
-19.97% |
Zealand Pharma A |
4 Q |
59.39% |
-348.01% |
- |
-109.74% |
Zogenix Inc |
4 Q |
93.83% |
- |
-18.63% |
-91.2% |
Zai Lab Limited |
2 Q |
65.49% |
-175.56% |
-28.9% |
-38.48% |
Zentalis Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-70.83% |
Zomedica Corp |
2 Q |
80.19% |
-103.98% |
- |
-7.34% |
Zosano Pharma Corporation |
1 Q |
34.85% |
-25309.85% |
- |
-172.07% |
Zoetis Inc |
2 Q |
72.16% |
30.73% |
-17.98% |
48.61% |
Zevra Therapeutics Inc |
2 Q |
92.01% |
-60.02% |
- |
-40.67% |
Zyversa Therapeutics Inc |
2 Q |
- |
- |
- |
0% |
Zymeworks Inc |
2 Q |
- |
-730.53% |
-563.88% |
46.66% |
Zynerba Pharmaceuticals Inc |
2 Q |
- |
- |
- |
-90.03% |